{"entity":{"id":"nct06603844","kind":"trial","name":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","aka":[],"tldr":"A phase 1/2 trial of CRB-601 monoclonal antibody in advanced solid tumours, run by Corbus Pharmaceuticals Inc., now recruiting.","summary":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT06603844 by Corbus Pharmaceuticals Inc., with 156 participants planned, started 2024-12-04 and due to reach its primary completion in 2026-11-01. Interventions recorded: CRB-601 monoclonal antibody and Anti-PD-1 monoclonal antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06603844","url":"https://clinicaltrials.gov/study/NCT06603844"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["corbus-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06603844","phase":"1/2","setting":"A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody Against Integrin avb8, in Patients With Advanced Solid Tumors","sponsor":"Corbus Pharmaceuticals Inc.","enrolled":156,"outcomes":[]},"route":"/trials/nct06603844/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/"}]}}